Virtus LifeSci Biotech Products ETF (BBP) Stock Price & Analysis
Virtus LifeSci Biotech Products ETF (BBP) closed at USD 102.07 on Friday, October 23, 2026, down 1.82% on the day. The US market is currently closed (after-hours); this is not a live price.
The prior close was USD 103.96; the Oct 23, 2026 session ranged USD 101.54–102.55 on volume of 9,836 shares. Market capitalization is —, with a 52-week range of USD 72.4–110.05 (PCX). Source: Nexqual, retrieved October 23, 2026 at 20:44 UTC.
Also available as compact Markdown for AI agents: nexqual.com/BBP.md
Key facts (BBP)
- Total return with dividends: 1Y +40.7% vs S&P 500 +13.4%; 5Y +97.2% vs S&P 500 +76.9%.
Total return (dividends reinvested) (BBP)
| 1Y (from 2025-10-24) | 5Y (from 2021-10-25) | |
|---|---|---|
| Total return | +40.7% | +97.2% |
| S&P 500 (SPY) | +13.4% | +76.9% |
| Per year | +40.9% | +14.6% |
| Volatility (annualized) | 26.6% | 25.0% |
| Max drawdown | -9.4% (Jul 2026→Jul 2026) | -30.0% (Nov 2021→May 2022) |
BBP options: expected move
| Expiration | Days | ATM implied volatility | Expected move |
|---|---|---|---|
| Nov 20, 2026 | 28 | 32.6% | ±7.3% |
| Dec 18, 2026 | 56 | 30.9% | ±9.7% |
| Jan 15, 2027 | 84 | 29.0% | ±11.2% |
| Apr 16, 2027 | 175 | 28.2% | ±15.9% |
30-day implied volatility 30% vs 31.6% realized over the last 30 trading days. Put/call ratio (volume) —. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.
Key Statistics (as of October 23, 2026 at 20:44 UTC)
| Price | USD 102.07 |
|---|---|
| Change | ▼ 1.82% (down) |
| Previous Close | USD 103.96 |
| Open | USD 102.49 |
| Day Range | USD 101.54 – 102.55 |
| 52-Week Range | USD 72.4 – 110.05 |
| Volume | 9,836 shares |
| Market Cap | — |
| Exchange | PCX |
Technical Analysis (BBP)
Nexqual's technical model rates BBP "STRONG SELL" based on 0 bullish and 5 bearish signals across 127 daily candles, as of October 23, 2026 at 20:44 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 45.93 (neutral) |
| vs SMA50 | Below (USD 104.76) |
| MACD | -0.2 (negative) |
Financial Health Score (BBP)
Nexqual rates Virtus LifeSci Biotech Products ETF's overall financial health "Mixed" across five dimensions, as of October 23, 2026 at 20:44 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Mixed — No data |
| Balance Sheet | Mixed — No data |
| Cash Flow | Mixed — No data |
| Efficiency | Mixed — No data |
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| BBC | Virtus Biotech Clinical Trials | USD 41.22 | ▼ 2.16% |
| SBIO | ALPS Medical Breakthroughs ETF | USD 53.38 | ▼ 2.14% |
| FBT | First Trust Amex Biotech Index | USD 269.25 | ▼ 1.26% |
| PBE | Invesco Biotechnology & Genome | USD 98.72 | ▼ 0.67% |
| PSCH | Invesco S&P SmallCap Health Car | USD 54 | ▼ 0.53% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 20:44 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt